FDA Torpedoes CytoDyn's Leronlimab for COVID-19 with Rare Public Scolding

FDA Torpedoes CytoDyn's Leronlimab for COVID-19 with Rare Public Scolding

Source: 
BioSpace
snippet: 

The U.S. Food and Drug Administration (FDA) published a “Statement on Leronlimab,” CytoDyn’s monoclonal antibody that was initially being developed for HIV and cancer before it began testing for COVID-19. In unusual public scolding, the agency accused the company of misrepresenting its clinical trial results for the drug in COVID-19.